# IL2RB

Source: https://onco.cc/targets/il2rb/  
OnCo record `il2rb` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.

## Summary

Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15.

Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.84, animal model 0.52, genetic association 0.00, clinical 0.96). In OnCo, 1 product record names it (Bempegaldesleukin).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: interleukin 2 receptor subunit beta; Interleukin-2 receptor subunit beta; CD122; IL15RB
- Tags: cancer-genes-wave
- Symbol: IL2RB
- Class: other
- Biology: Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. Location: Cell membrane (UniProt). Locus 22q12.3 (HGNC).
- Where found: Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Leukaemia: Open Targets association 0.53 with leukaemia (MONDO_0005059); Renal cell carcinoma: Open Targets association 0.52 with renal cell carcinoma (MONDO_0005086); Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908); Cutaneous T-cell lymphoma: Open Targets association 0.55 with primary cutaneous T-cell non-Hodgkin lymphoma (MONDO_0000607); Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6009: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6009
- UniProt P14784: https://www.uniprot.org/uniprotkb/P14784/entry
- NCBI Gene 3560: https://www.ncbi.nlm.nih.gov/gene/3560
- Ensembl ENSG00000100385: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100385

## Connected records

- collections: [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- drugs: [Bempegaldesleukin](https://onco.cc/drugs/bempegaldesleukin/)

---
JSON: https://onco.cc/api/v1/entities/il2rb.json